Business Wire

BCW Launches Brand Identity and Corporate Website

Del

BCW (Burson Cohn & Wolfe), a leading global communications agency, today revealed its brand identity expressed across a new brand mark, corporate website and suite of social media channels. The brand look and feel are designed to articulate the agency’s expertise in delivering integrated communications solutions for clients across all industry sectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180905005810/en/

BCW Launches Brand Identity and Corporate Website.

BCW Launches Brand Identity and Corporate Website.

“With BCW, we combined the deep expertise of our two heritage organizations – Burson-Marsteller and Cohn & Wolfe – to create an advanced agency to meet the needs of today’s clients and their targeted stakeholders,” said Donna Imperato, Global CEO, BCW. “We drive transformative results for our clients through big ideas rooted in earned media, backed up by data and analytics, and scaled across all channels. BCW is the agency I envisioned years ago, expert in delivering digitally driven, creative communications solutions across all marketing and communications disciplines. Our new identity, and especially our website, clearly illustrate those strengths.”

“The unmistakable focal point of our new website – www.bcw-global.com – is our work,” said Jim Joseph, Global President, Brand Solutions. “It’s clear from our client success stories that BCW is about combining world-class expertise in our legacy strengths with next-generation integrated solutions. And that’s exactly what we wanted to express with our new branding and logo – the union of the best of both our worlds to form something truly distinctive, fresh and innovative.”

The BCW network comprises more than 4,000 professionals on six continents including earned media experts, specialists skilled in research, analytics and insights; creative strategy and activation; digital, social and mobile innovation; and paid media. On August 14, 2018, BCW announced the acquisition of HZ, one of the largest independent, digitally driven, integrated creative agencies in the U.S., adding HZ’s nearly 200 creative and digital professionals to the BCW organization.

About BCW

BCW is one of the world’s largest full-service global communications agencies. Founded by the merger of Burson-Marsteller and Cohn & Wolfe, BCW delivers digitally and data-driven creative content and integrated communications programs grounded in earned media and scaled across all channels for clients in the B2B, consumer, corporate, crisis management, CSR, healthcare, public affairs and technology sectors. BCW is a part of WPP (NYSE:WPP), the world's leader in communications services. For more information visit www.bcw-global.com.

Contact information

For BCW:
Catherine Sullivan, 212-798-9501
Catherine.Sullivan@bm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting23.4.2019 08:38:00 CESTPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, today announced that new data from its lead development program, VTX-801 a novel investigational gene therapy for WD, and VTX-803, Vivet’ novel therapeutic in development for the treatment of PFIC3, have been accepted for oral presentation during the ASGCT 22nd Annual Meeting, April 29 - May 2, 2019 in Washington, D.C., USA. Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA will present data from a recently completed study, validating in WD mice the use of fecal excretion of IV-injected 64copper as a pharmacodynamic endpoint in the VTX-801 Phase I/II trial currently under preparation. These data are the first demonstration of copper homeostasis restoration with 64Copper in an animal model of WD through the delivery of a single, intravenous administration of

Transphorm Centers on the Simplicity and Reliability of High Voltage GaN Application Development at PCIM 201923.4.2019 08:00:00 CESTPressemelding

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V and 900 V gallium nitride (GaN) semiconductors—today shared a glimpse into its 2019 PCIM Europe showcase. Located in Hall 9 Booth 519, it centers on three key points to help conference attendees better understand Transphorm’s high voltage GaN value proposition: Reliability: Design with confidence when using Transphorm’s high quality, high reliability (Q+R) GaN transistors. Drivability: Pair Transphorm’s devices with off-the-shelf drivers, for easing drivability. Simplicity: Experience simpler designs due to minimal external gate drive circuitry along with standard packages, such as TO-220, TO-247, and PQFN, with well-known thermal management techniques. “At PCIM, you’ll see the culmination of Transphorm’s innovation along with its measurable impact on low volume as well as high volume customer applications,” said Philip Zuk, Vice President, Technical Marke

PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC23.4.2019 07:00:00 CESTPressemelding

A seminar titled “2H19 PV Market Outlook and Forecast” will be held in Shanghai on June 3, one day prior to SNEC, to discuss global supply chain market outlook in the second half of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005391/en/ 2019 Module Prices and Demand Forecast. (Photo: Business Wire) Held by PV InfoLink, a leading solar market intelligence provider, the seminar will bring together PV manufacturers, developers, EPC, and investors to explore major issues revolving the industry and help participants gain valuable insights for navigating the expanding solar market. PV InfoLink has invited Chinese major companies, including Jinko, Longi, and GCL-Si, to discuss impact of China’s transition to a subsidy-free market. This year, China’s demand will revive later than usual due to policy uncertainty. Moreover, Japan and India, China’s two major trading partners, saw weakening demand after the end of f

JPND Launches Updated Research and Innovation Strategy23.4.2019 06:45:00 CESTPressemelding

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative 1 has launched its updated global Research and Innovation Strategy (RIS) , to provide a unified framework for the support of world class research into neurodegenerative diseases. Neurodegenerative diseases are one of the world’s leading medical and societal challenges and there are now expected to be 50 million people worldwide suffering from Alzheimer’s disease and related disorders. Globally, these numbers show no signs of abating, and it is estimated that by 2050 in Europe alone, the total direct and informal care costs for Alzheimer’s and Parkinson’s disease will exceed €350 billion annually.2 JPND is the first and largest collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases. JPND’s ultimate goal is to accelerate the discovery of a cure and to enable early diagnosis for early personalised treatments. In the meantime, it is essential to implement

Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer22.4.2019 15:00:00 CESTPressemelding

Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and University of California San Diego, Moores Cancer Center (USA) (Razelle Kurzrock), aimed to expand precision oncology to patients with advanced solid tumors that progressed after treatment with standard therapies. For

PPG Advances Sustainability to Protect and Beautify the World22.4.2019 14:13:00 CESTPressemelding

PPG (NYSE:PPG) today published its 2018 Sustainability Report, detailing the company’s performance and progress against its 2025 sustainability goals that contribute to its purpose and promise: WE PROTECT AND BEAUTIFY THE WORLD™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190422005156/en/ PPG highlights progress against key economic, environment and social goals in its 2018 Sustainability Report. (Graphic: Business Wire) Last year, PPG embedded additional sustainable practices into its operations, introduced new sustainably advantaged products for customers, achieved a record low in injury cases across the company, advanced its global community engagement initiatives, and further advanced its diversity and inclusion efforts. The report is available at sustainability.ppg.com. “Our dedicated workforce continues to drive sustainability deeper into our global operations,” said Michael H. McGarry, PPG chairman and chief execu